Ipilimumab was also able to trigger ADCC via the engagement of FcyRIIIA receptors present on primary NK cells as well as NK cells and γδT cells activated by IL-2 by reacting with CTLA-4 present on melanoma cell lines and tissues. The gene discussed is IL2; the disease is melanoma.